Omnihealth Practice

CONFERENCE UPDATE: ASH 2023

Updates to the ASH guidelines on VTE: Thrombophilia testing and anticoagulation in COVID-19 patients

28 Feb 2024

Both thrombophilia (acquired or hereditary) and coronavirus disease 2019 (COVID-19) are associated with an increased risk of venous thromboembolism (VTE).^1,2ASH thus developed guidelines that aimed to provide evidence-based recommendations to support decision-making about thrombophilia testing and the use of anticoagulants for COVID-19 patients.^3,4 During the ASH Annual Meeting & Exposition 2023, Professor Saskia Middeldorp presented the ASH guidelines for thrombophilia testing which focused on whether testing for thrombophilia and tailoring management based on testing results would improve patient-important outcomes in different scenarios.¹ Subsequently, Dr. Deborah Siegal presented the ASH COVID-19 guidelines which focused on anticoagulant dose intensity in hospitalized COVID-19 patients and in those discharged after hospitalization who do not have suspected or confirmed VTE.⁴

While thrombophilia testing can improve risk stratification of VTE and guide the treatment and prevention of VTE, there is a risk of false negatives (missed diagnosis) and false positives (overdiagnosis), as well as potential physical, psychological, and financial harm to patients.¹ For each clinical question, the panel thus compared 2 scenarios: (a) thrombophilia testing and intervention only in individuals found to have thrombophilia and (b) no thrombophilia testing and usual care in all individuals.¹For each recommendation, the panel considered the risk of bleeding vs. recurrent thrombosis, the cost and burden of thrombophilia testing and anticoagulant treatment, as well as patient preference.¹ In total 23 recommendations were provided with nearly all recommendations based on very low certainty in the evidence due to modeling assumptions (table 1).³

Recommendation (R) no.	Population	Recommendation	Strength, certainty in evidence
Patients with symptomatic VTE
R1	Unprovoked VTE	Do not test for thrombophilia	Conditional, very low
R2	VTE provoked by surgery	Do not test for thrombophilia	Conditional, very low
R3	VTE provoked by nonsurgical major transient risk factor	Test for thrombophilia, and indefinite anticoagulant treatment for patients with thrombophilia	Conditional, very low
R4	VTE provoked by pregnancy or postpartum	Test for thrombophilia, and indefinite anticoagulant treatment for patients with thrombophilia	Conditional, very low
R5	VTE associated with use of COC	Test for thrombophilia, and indefinite anticoagulant treatment for patients with thrombophilia	Conditional, very low
R6	An unspecified type of VTE (i.e., not specified as provoked or unprovoked VTE)	Do not test for thrombophilia	Conditional, very low
Patients with symptomatic VTE in unusual sites
R7	CVT	(a) In settings when anticoagulation would otherwise be discontinued after primary short-term treatment: test for thrombophilia, and indefinite anticoagulant treatment for patients with thrombophilia	Conditional, very low
R8	CVT	(b) In settings when anticoagulation would otherwise be continued indefinitely: do not test for thrombophilia	Conditional, very low
R9	Splanchnic venous thrombosis	(a) In settings when anticoagulation would otherwise be discontinued after primary short-term treatment: test for thrombophilia, and indefinite anticoagulant treatment for patients with thrombophilia	Conditional, very low
R10	Splanchnic venous thrombosis	(b) In settings when anticoagulation would otherwise be continued indefinitely: do not test forthrombophilia	Conditional, very low
Asymptomatic individuals with a family history of VTE and/or thrombophilia
Individuals with a minor transient risk factor for VTE
R11	Individuals with a family history of VTE and known thrombophilia	Strategy #1: Selective testing for the thrombophilia known in the family
	Heterozygous FVL or heterozygous PGM	Do not test for thrombophilia	Conditional, very low
	Protein C, S, or antithrombin deficiency	Test for the thrombophilia known in the family and use thromboprophylaxis in individuals with thrombophilia	Conditional, very low
R12	Individuals with a family history of VTE and known thrombophilia	Strategy #2: Doing a thrombophilia panel
	Heterozygous FVL or heterozygous PGM	Do not test for a panel of hereditary thrombophilias (panel)	Conditional, very low
	Protein C, S, or antithrombin deficiency	Test for all hereditary thrombophilia (panel) and use thromboprophylaxis in individuals with thrombophilia	Conditional, very low
R13	Individuals with a family history of VTE and unknown thrombophilia status	Do not test for thrombophilia	Conditional, very low
R14	Individuals with a family history of thrombophilia but no VTE
	Heterozygous FVL or heterozygous PGM	Do not test for thrombophilia	Conditional, very low
	Protein C, S, or antithrombin deficiency in first-degree relatives	Test for the thrombophilia known in the family and use thromboprophylaxis in individuals with thrombophilia	Conditional, very low
	Protein C, S, or antithrombin deficiency in second-degree relatives	Either test or do not test for the thrombophilia known in the family to guide thromboprophylaxis	Conditional, very low
Women considering using COC or HRT
R15	Women from the general population considering COCs	Do not test for thrombophilia	Strong, low
R16	Women from the general population considering HRT	Do not test for thrombophilia	Conditional, low
R17	Women with a family history of VTE and unknown thrombophilia in the family considering COCs	Do not test for thrombophilia	Conditional, very low
R18	Women with a family history of VTE and unknown thrombophilia in the family considering HRT	Do not test for thrombophilia	Conditional, very low
R19	Women with a family history of VTE and thrombophilia considering COCs	Strategy: Selective testing for the thrombophilia known in the family
	FVL or PGM	Do not test for thrombophilia	Conditional, very low
	Protein C, S, or antithrombin deficiency	Test for thrombophilia and avoid COCs in women with thrombophilia	Conditional, very low
R20	Women with a family history of VTE and thrombophilia considering HRT	Strategy: Selective testing for the thrombophilia known in the family
	FVL or PGM	Do not test for thrombophilia	Conditional, very low
	Protein C, S, or antithrombin deficiency	Test for thrombophilia and avoid HRT in women with thrombophilia	Conditional, very low
Women who are planning pregnancy
Antepartum prophylaxis
R21	Women with a family history of VTE and thrombophilia	Strategy: Selective testing for the thrombophilia known in the family
	Known homozygous FVL, combination of FVL and PGM, or antithrombin deficiency	Test for the thrombophilia known in the family and use antepartum thromboprophylaxis in women with thrombophilia	Conditional, very low
	Known protein C or protein S deficiency in the family	Either test or do not test for the thrombophilia known in the family to guide antepartum thromboprophylaxis	Conditional, very low
Postpartum prophylaxis
R22	Women with a family history of VTE and thrombophilia	Strategy: Selective testing for the thrombophilia known in the family
	Known homozygous FVL, combination of FVL and PGM, or antithrombin, protein C, or protein S deficiency	Test for the thrombophilia known in the family and use postpartum thromboprophylaxis in women with thrombophilia	Conditional, very low
	Known combination of FVL and PGM, or antithrombin deficiency in second-degree relatives	Test for the thrombophilia known in the family and use postpartum thromboprophylaxis in women with thrombophilia	Conditional, very low
	Known protein C or protein S deficiency in the family	Either test or do not test for the thrombophilia known in the family to guide postpartum thromboprophylaxis	Conditional, very low
Patients with cancer
R23	Ambulatory patients with cancer who are classified to be at low or intermediate risk for VTE, who have a family history of VTE in first-degree relatives	Strategy: Doing a thrombophilia panel test for all hereditary thrombophilia (panel) and use thromboprophylaxis in individuals with thrombophilia	Conditional, very low

Table 1: Summary of recommendations for thrombophilia testing³

COC: Combined oral contraceptive; CVT: Cerebral venous thrombosis; FVL: Factor V Leiden; HRT: Hormone replacement therapy; PGM: Prothrombin 20210A gene mutation; R: Recommendation; VTE: Venous thromboembolism

Similarly, recognizing and minimizing the risk of harm from anticoagulants is a critical component for the treatment of VTE in COVID-19 patients.⁴The updated ASH focused on providing recommendations on adjusting the intensity of anticoagulants for acutely or critically ill hospitalized COVID-19 patients, and for patients who were discharged after hospitalization for COVID-19 who do not have suspected or confirmed VTE (table 2).^2,4 The guideline also included an initial phase and a living phase, during which monthly updated searches for baseline risk estimates, prognostic factors, and the effect of anticoagulation strategies are performed, allowing guideline recommendations to be continuously revisited if new evidence meets pre-specified criteria.⁴

Recommendation	Strength, certainty in evidence
R1: The ASH guideline panel suggests using prophylactic-intensity over intermediate-intensity or therapeutic-intensity anticoagulation for patients with COVID-19-related critical illness who do not have suspected or confirmed VTE	Conditional, very low
R2a: The ASH guideline panel suggests using prophylactic-intensity over intermediate-intensity anticoagulation for patients with COVID-19-related acute illness who do not have suspected or confirmed VTE R2b; The ASH guideline panel suggests using therapeutic-intensity over prophylactic-intensity anticoagulation for patients with COVID-19-related acute illness who do not have suspected or confirmed VTE	Conditional, very low
R3: The ASH guideline panel suggests against using post-discharge prophylactic-intensity anticoagulation in patients with COVID-19 discharged from the hospital who do not have suspected or confirmed VTE	Conditional, very low

Table 2: Summary of recommendations on the use of anticoagulation in COVID-19 patients^2,4

ASH: American Society of Hematology; COVID-19: Coronavirus disease 2019; R: Recommendation; VTE: Venous thromboembolism

Get access to our exclusive articles.

Benign prostatic hyperplasia patients have a higher risk of urological complications after COVID-19 infection

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative organism of coronavirus disease 2019 (COVID-19), can also affect many extra-respiratory systems.1 As viral entry into host cells is facilitated by the interaction between the SARS-CoV-2 spike and angiotensin-converting enzym

UROLOGY

09 May 2024

Nirmatrelvir-ritonavir therapy demonstrated manageable tolerability among COVID-19 patients with CKD

Despite being an effective oral antiviral therapy for coronavirus 2019 (COVID-19), nirmatrelvir-ritonavir (NMV-r) was not approved for patients with an estimated glomerular filtration rate (eGFR) <30mL/min/1.75m2.1 This can be attributed to a phenomenon known as “renalism”, which is the frequent exc

INFECTIOUS DISEASE

06 Sep 2023

Update on COVID-19 infection and vaccination management in SLE

The prevalence of Coronavirus disease 2019 (COVID-19) in systemic lupus erythematosus (SLE) patient is higher than in the normal population and SLE patients being associated with higher risk of death from COVID-19.1 The COVID-19 Treatment Guidelines Panel (hereinafter referred to as “The Panel”) fro

RHEUMATOLOGY

09 Feb 2023

Managing difficult-to-treat infections in immunocompromised patients

Infections by multidrug-resistant organisms (MDROs), especially Gram-negative rods, are associated with higher mortality, higher morbidity, longer hospital stay and increased public healthcare costs.¹For patients infected with carbapenemase-producing Enterobacteriaceae (CPE), few effective antibiot

HEMATOLOGY INFECTIOUS DISEASE

07 Jul 2021

An early portrait of neuropathological features of COVID-19

An outbreak of atypical pneumonia caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was initially reported in December 2019 from Wuhan in China.¹ Since then, over 44 million people worldwide have been affected by the novel coronavirus disease 2019 (COVID-19).² Owing to a high proportion of cases being asymptomatic or mildly symptomatic, the complete denominator of COVID-19 remains unknown.¹ While literature is replete with pulmonary manifestations of COVID-19, its neurological complications are being increasingly recognized.¹

NEUROLOGY INFECTIOUS DISEASE

30 Jun 2021

Updated Guidelines for the Management of Venous Thromboembolism (VTE)

A multidisciplinary guideline panel from the American Society of Hematology (ASH), with support from the McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre, has drafted a list of 28 recommendations for the initial venous thromboembolism (VTE) managem

HEMATOLOGY

27 Feb 2021

Balancing the risk and benefit of anticoagulation in cancer patients with high bleeding risk

Bleeding is a common problem estimated to occur in 6-10% of advanced cancer patients.1 Bleeding can be caused by the cancer itself, be related to radiation or chemotherapy treatment, or exacerbated by immunotherapies and anticoagulants.2 Patients may also be predisposed to bleeding due to thrombocyt

ONCOLOGY

27 Dec 2020

Dive into the future of thrombosis management

At the 25^th European Hematology Association Annual Congress (EHA25), three researchers presented the latest findings on the role of gut microbiome, microvesicles (MVs) and neutrophil extracellular traps (NETs) in thrombosis. Understanding the implications of these key players would enable a more comprehensive prevention and

HEMATOLOGY

01 Sep 2020

New interim guidelines for rheumatic and musculoskeletal diseases management in the context of COVID-19

During the EULAR 2020 e-congress, Dr. Robert Landewé, MD, Ph.D., Professor of the Amsterdam Rheumatology Center at the University of Amsterdam, and chair of the Department of Rheumatology at the Zuyderland Medical Center Heerlen, the Netherland, shared his perspective on the provisional EULAR

RHEUMATOLOGY

01 Sep 2020

Nasopharyngeal carcinoma management: Advances and hope

Nasopharyngeal carcinoma (NPC) is a difficult-to-treat malignancy due to its proximity to critical structures. It was once the fourth most common cancer in Hong Kong.¹ Now, it is one of the most successful stories in oncology as the cancer has become much less prevalent and less lethal over

ONCOLOGY

31 Aug 2020